Viking Therapeutics VKTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $150.15M-2.2% | $153.46M+70.6% | $89.95M+49.5% | $60.15M+45.3% | $41.39M+33.6% | ||
| $13.98M+23.9% | $11.28M+31.0% | $8.61M-40.3% | $14.42M+2.4% | $14.08M-7.7% | ||
| $164.13M-0.4% | $164.74M+67.1% | $98.56M+32.2% | $74.57M+34.4% | $55.47M+20.0% | ||
| $164.13M-0.4% | $164.74M+67.1% | $98.56M+32.2% | $74.57M+34.4% | $55.47M+20.0% | ||
| -$164.13M+0.4% | -$164.74M-67.1% | -$98.56M-32.2% | -$74.57M-34.4% | -$55.47M-20.0% | ||
| $5.8M-17.6% | $7.04M-9.5% | $7.77M-14.0% | $9.03M-8.4% | $9.86M-9.0% | ||
| $5.8M-18.0% | $7.08M-9.0% | $7.77M-13.7% | $9.01M-8.4% | $9.84M-9.1% | ||
| —— | $13.75K0.0% | $13.75K0.0% | $13.75K0.0% | $13.75K+1,275% | ||
| -$158.33M-0.4% | -$157.66M-73.7% | -$90.79M-38.5% | -$65.56M-43.7% | -$45.63M-28.8% | ||
| -$1.37+1.4% | -$1.39-71.6% | -$0.81-39.7% | -$0.58-41.5% | -$0.41-28.1% | ||
| -$1.37+1.4% | -$1.39-71.6% | -$0.81-39.7% | -$0.58-41.5% | -$0.41-28.1% | ||
| 115.6M+2.6% | 112.7M+0.3% | 112.3M+0.2% | 112.1M+0.1% | 112.1M+2.8% | ||
| 115.6M+2.6% | 112.7M+0.3% | 112.3M+0.2% | 112.1M+0.1% | 112.1M+2.8% | ||
| $5.8M-17.6% | $7.04M-9.5% | $7.77M-14.0% | $9.03M-8.4% | $9.86M-9.0% | ||
| $0— | $0-100% | $8K-66.7% | $24K0.0% | $24K0.0% | ||
| -$159.56M-1.2% | -$157.66M-74.7% | -$90.25M-37.8% | -$65.51M-45.4% | -$45.06M-19.1% | ||
| $16K+14.3% | $14K— | $0-100% | $24K+167% | $9K+105% | ||
| -$1.25M— | $0-100% | $540K+1,977% | $26K-95.4% | $563K+125% | ||
| $5.8M-18.0% | $7.08M-9.0% | $7.77M-13.7% | $9.01M-8.4% | $9.84M-9.1% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$164.13M+0.4% | -$164.74M-67.1% | -$98.56M-32.2% | -$74.57M-34.4% | -$55.47M-20.0% | ||
| -$164.13M+0.4% | -$164.74M-67.1% | -$98.56M-32.2% | -$74.57M-34.4% | -$55.47M-20.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viking Therapeutics's income statement data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.